Adaptimmune Therapeutics PLC — Director's Dealing 2020

Jun 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2020-05-29

Reporting Person: Noble James (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-29	American Depositary Shares	S	500000	$9.332	Disposed	0	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019.

F2: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $9.02 to $10.13, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote.

F3: The ADSs reported in this Column 4 represent solely those ADSs that were sold pursuant to a Rule 10b5-1 trading plan. Additionally, the reporting person holds 8,145,700 ordinary shares and share options covering an aggregate of 9,137,960 ordinary shares of the Issuer.